With regard to the use of anti-CD19 IL-15-secreting CAR-NK cells for the treatment of patients with B-cell lymphoma and chronic lymphocytic leukemia (CLL), 8 of 11 (73%) patients with relapsed or refractory CD19-positive cancer achieved a response; 7 of these patients (lymphoma, 4 patients; and CLL, 3 patients) achieved CR, and 1 patient achieved a response with Richter’s transformation component, but had persistent CLL (101). The gene discussed is CD19; the disease is lymphoma.